Develop Business Strategies Of Multiple Sclerosis Market Analysis and Global Forecast to 2026

"The Latest Research Report PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2026 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

Multiple Sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection, and neurodegeneration within the central nervous system. It is the most common cause of non-traumatic neurological disability in young adults, afflicting at least 2.5 million people worldwide. In most patients, the disease is characterized initially by episodes of reversible neurological deficits, which is often followed by progressive neurological deterioration over time. The precise etiology of MS remains incompletely elucidated, but it is believed to involve a complex interaction between various environmental and genetic factors.

The late-stage candidates include products from both established and emerging players with a wide range of mechanism of action (MOA). Progressive MS is a significant focus for product development, with 8 of the late-stage products targeting this patient group as an initial indication, such as protecting mitochondrial energy sources (idebenone), antioxidants (MD1003), promoting remyelination (opicinumab) and neuroprotection (ibudilast and laquinimod). There is currently a distinct lack of DMT options for patients with progressive MS subtypes, and patients remain significantly underserved. The majority of the Phase III candidates targeting RRMS are based on established MOAs, such as second generation S1P receptor modulators (ozanimod and ponesimod) or anti-CD20 mAbs (ofatumumab and ublituximab).

Get Sample Copy of this report @ https://www.marketresearchreports.biz/sample/sample/1607656

Scope

- Overview of MS: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized MS market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (RRMS, PPMS and SPMS), forecast from 2016 to 2026.
- Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the MS therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for MS therapy. Promising candidates in Phase IIB or above were profiled.
- Analysis of the current and future market competition in the global MS therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global MS therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MS therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Browse Complete Report with TOC @ https://www.marketresearchreports.biz/reports/1607656/pharmapoint-multiple-sclerosis-global-market-research-reports/toc

Table of Contents

1 Table of Contents 2
1.1 List of Tables 8
1.2 List of Figures 11
2 Executive Summary 12
2.1 Moderate Growth Expected in the MS Market from 2016 to 2026 13
2.2 R&D and Corporate Strategies within the MS Market 14
2.3 Current Treatments Leave a High Level of Unmet Need in the MS Market 16
2.4 Opportunities Remain for Products that Will Fulfill Significant Unmet Needs in the MS Market 17
2.5 Late-Stage Pipeline Drugs Entering the MS Market Will Be a Key Driver of Growth 18
2.6 What Do the Physicians Think? 19
3 Introduction 23
3.1 Catalyst 23
3.2 Related Reports 24
4 Disease Overview 25
4.1 Etiology and Pathophysiology 25
4.1.1 Etiology 25
4.1.2 Pathophysiology 26
4.2 Classification 27
4.2.1 Relapse-Remitting MS 27
4.2.2 Secondary Progressive MS 27
4.2.3 Primary Progressive MS 28
4.2.4 Progressive Relapsing MS 28
4.3 Symptoms 29
4.4 Prognosis 30
4.5 Quality of Life 31
5 Epidemiology 32
5.1 Disease Background 32
5.2 Risk Factors and Comorbidities 32
5.3 Global and Historical Trends 33
5.4 Forecast Methodology 35
5.4.1 Sources 35
5.4.2 Forecast Assumptions and Methods 38
5.4.3 Diagnosed Prevalent Cases of MS 38
5.4.4 Diagnosed Prevalent Cases of MS by Types 42
5.4.5 Diagnosed Incident Cases of MS 44
5.5 Epidemiological Forecast for MS (2016-2026) 47
5.5.1 Diagnosed Prevalent Cases of MS 47
5.5.2 Age-Specific Diagnosed Prevalent Cases of MS 48
5.5.3 Sex-Specific Diagnosed Prevalent Cases of MS 48
5.5.4 Diagnosed Prevalent Cases of MS by Types 49
5.5.5 Diagnosed Incident Cases of MS 50
5.5.6 Age-Specific Diagnosed Incident Cases of MS 51
5.5.7 Sex-Specific Diagnosed Incident Cases of MS 52
5.6 Discussion 53
5.6.1 Epidemiological Forecast Insight 53
5.6.2 Limitation of Analysis 54
5.6.3 Strengths of Analysis 55

View Sample PDF @
https://www.marketresearchreports.biz/reports/1607656/pharmapoint-multiple-sclerosis-global-market-research-reports.pdf

6 Disease Management 56
6.1 Diagnosis Overview 56
6.2 Treatment Overview 59
6.2.1 Management of Acute Relapse 60
6.2.2 Treatment with Disease-Modifying Therapies 61
6.2.3 Challenges in Drug Selection as More DMTs Enter the MS Market 61
6.2.4 Shifting MS Treatment Paradigms Unfolding as New DMTs and New Data Become Available 63
6.2.5 Symptomatic Therapies 65
6.3 US 66
6.3.1 Diagnosis 66
6.3.2 Drug Treatment 67
6.4 France 71
6.4.1 Diagnosis 71
6.4.2 Drug Treatment 72
6.5 Germany 74
6.5.1 Diagnosis 74
6.5.2 Drug Treatment 75
6.6 Italy 77
6.6.1 Diagnosis 77
6.6.2 Drug Treatment 77
6.7 Spain 79
6.7.1 Diagnosis 79
6.7.2 Drug Treatment 80
6.8 UK 82
6.8.1 Diagnosis 82
6.8.2 Drug Treatment 83
6.9 Japan 85
6.9.1 Diagnosis 85
6.9.2 Drug Treatment 86

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.